Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

ENZ opened at $1.13 on Wednesday. The stock has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.11. Enzo Biochem has a 1 year low of $0.99 and a 1 year high of $1.50.

Institutional Investors Weigh In On Enzo Biochem

A hedge fund recently raised its stake in Enzo Biochem stock. XTX Topco Ltd raised its holdings in Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,262 shares of the medical research company’s stock after acquiring an additional 13,735 shares during the quarter. XTX Topco Ltd owned about 0.05% of Enzo Biochem worth $31,000 at the end of the most recent quarter. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.